Stocks News

LAST PRICE
36.1400
TODAY'S CHANGE (%)
Trending Down-0.0800 (-0.2209%)

Bid / Lots
34.6700/ 1
Ask / Lots
39.5400/ 1
Open / Previous Close
36.5500 / 36.2200
Day Range
Low 36.1100
High 37.2100
52 Week Range
Low 25.5300
High 39.3700
Volume
283,774
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 13, 2024
- Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference, from 4:30PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:30PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: SUPN
  
  Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
  
  ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London, United Kingdom.
Nov 12, 2024
- Supernus Pharmaceuticals Insider Sold Shares Worth $4,536,250, According to a Recent SEC Filing, from 4:30PM ET on Tuesday Nov 12, 2024 by MT Newswires
  4:30PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: SUPN
  04:30 PM EST, 11/12/2024 (MT Newswires) -- Jack A. Khattar, Director, President, CEO, on November 08, 2024, sold 125,000 shares in Supernus Pharmaceuticals (SUPN) for $4,536,250. Following the Form 4 filing with the SEC, Khattar has control over a t...
- Supernus Pharmaceuticals Insider Sold Shares Worth $391,568, According to a Recent SEC Filing, from 4:28PM ET on Tuesday Nov 12, 2024 by MT Newswires
  4:28PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: SUPN
  04:28 PM EST, 11/12/2024 (MT Newswires) -- Georges Gemayel, Director, on November 08, 2024, sold 10,787 shares in Supernus Pharmaceuticals (SUPN) for $391,568. Following the Form 4 filing with the SEC, Gemayel has control over a total of 13,315 shar...
Nov 8, 2024
- Supernus Pharmaceuticals Insider Sold Shares Worth $520,480, According to a Recent SEC Filing, from 4:18PM ET on Friday Nov 08, 2024 by MT Newswires
  4:18PM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: SUPN
  04:18 PM EST, 11/08/2024 (MT Newswires) -- Georges Gemayel, Director, on November 07, 2024, sold 14,213 shares in Supernus Pharmaceuticals (SUPN) for $520,480. Following the Form 4 filing with the SEC, Gemayel has control over a total of 13,315 shar...
Nov 5, 2024
- Supernus Pharmaceuticals Q3 Swings to Profit, Revenue Increases; 2024 Revenue Outlook Lifted, from 5:20AM ET on Tuesday Nov 05, 2024 by MT Newswires
  5:20AM ET on Tuesday Nov 05, 2024 by MT Newswires
  Companies Mentioned: SUPN
  05:20 AM EST, 11/05/2024 (MT Newswires) -- Supernus Pharmaceuticals (SUPN) reported Q3 earnings late Monday of $0.69 per diluted share, swinging from a loss of $0.29 a year earlier. A single analyst polled by Capital IQ expected $0.02. Revenue for t...

Today
- Top Premarket Gainers, from 14 hours ago by MT Newswires
  14 hours ago by MT Newswires
  Companies Mentioned: QTTB, RGTI, WLDS, PAHC, QMCO
Nov 18, 2024
- Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse, from 6:01AM ET on Monday Nov 18, 2024 by Newsfile
  6:01AM ET on Monday Nov 18, 2024 by Newsfile
  Companies Mentioned: ELTP
- Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse, from 6:01AM ET on Monday Nov 18, 2024 by Dow Jones
  6:01AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: ELTP
Nov 15, 2024
- Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration, from 5:00PM ET on Friday Nov 15, 2024 by Dow Jones
  5:00PM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: EGRX
Nov 14, 2024
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information, from 4:39PM ET on Thursday Nov 14, 2024 by Newsfile
  4:39PM ET on Thursday Nov 14, 2024 by Newsfile
  Companies Mentioned: ELTP
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information, from 4:39PM ET on Thursday Nov 14, 2024 by Dow Jones
  4:39PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: ELTP
Nov 12, 2024
- DJ Phibro Animal Health Is Maintained at Underweight by Barclays, from 10:15AM ET on Tuesday Nov 12, 2024 by Dow Jones
  10:15AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: PAHC
- Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: EGRX
Nov 7, 2024
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024, from 7:02AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:02AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: ELTP
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024, from 7:01AM ET on Thursday Nov 07, 2024 by Newsfile
  7:01AM ET on Thursday Nov 07, 2024 by Newsfile
  Companies Mentioned: ELTP

Supernus Pharmaceuticals Inc
NASDAQ:SUPNUnited States

Search Criteria

Nov 13, 2024

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference, from 4:30PM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Supernus Pharmaceuticals Insider Sold Shares Worth $4,536,250, According to a Recent SEC Filing, from 4:30PM ET on Tuesday Nov 12, 2024 by MT Newswires

Supernus Pharmaceuticals Insider Sold Shares Worth $391,568, According to a Recent SEC Filing, from 4:28PM ET on Tuesday Nov 12, 2024 by MT Newswires

Nov 8, 2024

Supernus Pharmaceuticals Insider Sold Shares Worth $520,480, According to a Recent SEC Filing, from 4:18PM ET on Friday Nov 08, 2024 by MT Newswires

Nov 5, 2024

Supernus Pharmaceuticals Q3 Swings to Profit, Revenue Increases; 2024 Revenue Outlook Lifted, from 5:20AM ET on Tuesday Nov 05, 2024 by MT Newswires

Peers Headlines

Today

Top Premarket Gainers, from 14 hours ago by MT Newswires

Nov 18, 2024

Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse, from 6:01AM ET on Monday Nov 18, 2024 by Newsfile

Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse, from 6:01AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 15, 2024

Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration, from 5:00PM ET on Friday Nov 15, 2024 by Dow Jones

Nov 14, 2024

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information, from 4:39PM ET on Thursday Nov 14, 2024 by Newsfile

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information, from 4:39PM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 12, 2024

DJ Phibro Animal Health Is Maintained at Underweight by Barclays, from 10:15AM ET on Tuesday Nov 12, 2024 by Dow Jones

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Nov 7, 2024

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024, from 7:02AM ET on Thursday Nov 07, 2024 by Dow Jones

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024, from 7:01AM ET on Thursday Nov 07, 2024 by Newsfile